Dr Louis Nisbet leads BioCity forward

BioCity Nottingham appoints new chairman

Louis Nisbet has become chairman of BioCity Nottingham in the UK. He will oversee the expansion of BioCity’s services to cater for increasing demand from both UK and international tenants. The recent arrival of former AstraZeneca and Pfizer employees launching new ventures, as well as the rapid growth of several existing tenants, makes the BioCity bioscience cluster an attractive central UK business location.

Marlow-based Nisbet is a venture partner with Kurma BioFund, Paris. His early pharmaceutical career in drug discovery research with Roche, Glaxo and Smith Kline gives him a global insight into the issues surrounding the development and commercialisation of new healthcare products and businesses. He will devote time in Nottingham with fellow Board directors to addressing the needs of new life science companies, in particular their financing requirements.

Nisbet said: ‘We will be looking to work with our clients and the large pharmaceutical companies, as well as private investors, to find innovative solutions to facilitate partnerships and financing that will suit everyone.’

You may also like

Finance

BioCity predicts proliferation of workspace amid life science ventures boom

The UK's life science incubator has released the Life Science Start-Up Report with in-depth analysis of emerging businesses
Finance

BioCity makes FT 1000 list of Europe's fastest growing companies

The list identified BioCity and one of the companies on one of its sites in top 200 in the UK for fastest growth
Research & Development

£1.4m to boost growing space for life sciences companies

A £1.4million investment will provide more space for life sciences companies at a Nottingham Enterprise Zone site, thanks to funding from the D2N2 Local Enterprise Partnership, Boots and MediCity
Research & Development

BioCity to support Pfizer scientists facing redundancy

Package of support could lead to new start-up ventures for staff from Sandwich, Kent plant
Packaging

SGD Pharma acquires Alphial Srl in a strategic step forward

SGD Pharma is pleased to announce an agreement with Italian Private Equity firm Entangled Capital to acquire Alphial Srl, a leading producer of tubular vials and ampoules headquartered in Italy
Finance

Piramal and NewAmsterdam Pharma invest in a dedicated suite to enhance oral solid dosage production

The multimillion-dollar investment provides NewAmsterdam Pharma with the commercial capacity to produce a fixed-dose combination (FDC) of obicetrapib and ezetimibe to meet commercial demand
Pharmaceutical

Enanta Pharma files patent infringement suit against Pfizer in the Unified Patent Court of the EU

The company is seeking a determination of liability for use and infringement of European Patent No. EP 4 051 265 (the 265 Patent) in the manufacture, use and sale of Pfizer’s COVID-19 antiviral, Paxlovid (nirmatrelvir tablets; ritonavir tablets)
Subscribe now